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Abstract
 
We examined the immune response to DBY, a model H-Y minor histocompatibility antigen
(mHA) in a male patient with chronic graft-versus-host disease (GVHD) after allogeneic
hematopoietic stem cell transplant from a human histocompatibility leukocyte antigen (HLA)-
identical female sibling. Patient peripheral blood mononuclear cells were screened for reactivity
against a panel of 93 peptides representing the entire amino acid sequence of DBY. This
epitope screen revealed a high frequency CD4
 
  
 
T cell response to a single DBY peptide that
persisted from 8 to 21 mo after transplant. A CD4
 
  
 
T cell clone displaying the same reactivity
was established from posttransplant patient cells and used to characterize the T cell epitope as
a 19-mer peptide starting at position 30 in the DBY sequence and restricted by HLA-
DRB1
 
*
 
1501. Remarkably, the corresponding X homologue peptide was also recognized by
donor T cells. Moreover, the T cell clone responded equally to mature HLA-DRB1
 
*
 
1501
male and female dendritic cells, indicating that both DBY and DBX peptides were endoge-
nously processed. After transplant, the patient also developed antibodies that were specific for
recombinant DBY protein and did not react with DBX. This antibody response was mapped
to two DBY peptides beginning at positions 118 and 536. Corresponding DBX peptides were
not recognized. These studies provide the first demonstration of a coordinated B and T cell
immune response to an H-Y antigen after allogeneic transplant. The specificity for recipient
male cells was mediated by the B cell response and not by donor T cells. This dual DBX/DBY
antigen is the first mHA to be identified in the context of chronic GVHD.
Key words: minor histocompatibility antigen • chronic graft-versus-host disease • 
hematopoietic stem cell transplantation • H-Y antigen • class II epitope
 
Introduction
 
Minor histocompatibility antigens (mHAs) are critical targets
of immune responses after allogeneic hematopoietic stem
cell transplantation (HSCT; 1). In patients who receive
stem cell transplants from HLA-matched donors, mHAs are
presumed to be the primary antigenic targets of GVHD (1).
This immune response results in significant morbidity and
mortality after allogeneic HSCT. However, mHAs are also
expressed on recipient leukemia cells, and targeting these
same antigens on tumor cells results in a graft-versus-leukemia
(GVL) effect that reduces the incidence of relapse after
transplant (2, 3). With the importance of these antigens as
targets of both GVHD and GVL, their precise identification
and characterization of the immune responses they elicit can
have significant impact on the outcome of allogeneic HSCT.
mHAs have traditionally been identified as discrete peptides
recognized by donor T cells after allogeneic HSCT. These
peptides can be presented by either MHC class I or class II
molecules and both CD8
 
  
 
and CD4
 
  
 
donor T cell responses
have been described. Although alternative mechanisms for
generating mHAs have recently been identified (4), most
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mHAs reflect genetic disparities between recipient and
donor in regions outside of the MHC gene complex. For
example, HA-1, HA-2, HA-3, and HA-8 are each en-
coded by autosomal genes with a coding single nucleotide
polymorphism that distinguishes the recipient from the
stem cell donor (5–8). Each single nucleotide polymor-
phism results in the generation of an immunogenic T cell
antigen in recipient cells that is recognized by donor T
cells after HSCT. In male patients with female donors,
H-Y antigens constitute a distinct class of mHAs (9). In H-Y
mHAs, the antigenic peptides are encoded by ubiqui-
tously expressed male-specific genes located on the nonre-
combining region of the Y chromosome. Although each
of these genes has an expressed X homologue, each gene
pair has significant disparity at the amino acid level (10–
17). Thus far, all T cell H-Y epitopes that have been iden-
tified include disparate amino acid residues that appear to
be essential for their immunogenicity. Upon transplanta-
tion into male patients, female donor T cells recognize
these H-Y mHAs as “non-self” and elicit a strong im-
mune response directed at recipient cells in vivo. Clini-
cally, the relevance of H-Y antigens is evidenced by the
increased risk of GVHD in male patients transplanted with
female stem cells by comparison to other recipient/donor
sex combinations (18).
In recent studies, our laboratory has demonstrated that
H-Y mHAs also elicit a potent B cell response after alloge-
neic HSCT (19). Using DBY as a model H-Y mHA, we
demonstrated that 
 
 
 
50% of male patients who receive stem
cells from female donors develop a high titer antibody re-
sponse to recombinant DBY protein. Antibodies to DBY
did not react with recombinant DBX homologue, were
not present before transplant, and were rarely detected in
male patients with male stem cell donors. Using a set of
synthetic peptides encompassing the entire sequence of the
DBY protein, the antibody response after transplant was
primarily mapped to regions of amino acid disparity be-
tween DBY and DBX.
In this study, we undertook a comprehensive analysis of
T and B cell immune responses elicited by DBY mHA in a
male patient who developed chronic GVHD after trans-
plantation with HLA-identical female donor stem cells.
Using ELISPOT to detect specific T cell responses, un-
manipulated patient T cells were screened for reactivity
against a panel of 93 peptides representing the entire
amino acid sequence of DBY. We subsequently isolated
clonal CD4
 
  
 
T cells in vitro that reacted with a single
DBY peptide. In parallel, patient serum was also screened
for antibodies specific for DBY. Here we demonstrate that
DBY elicited a coordinated and sustained CD4
 
  
 
helper T
and B cell response. Both T and B cell epitopes were
mapped to distinct regions of the DBY protein. Remark-
ably, the differential recognition of DBY compared with
DBX was only observed at the B cell level, emphasizing
the potential significance of the antibody component in
the development of mHA-specific immune responses in
chronic GVHD.
 
Materials and Methods
 
Patient Characteristics.
 
The patient studied in this report is a
44-yr-old male diagnosed with acute myeloid leukemia (M2
subtype) in December 2000. He responded to induction chemo-
therapy and achieved complete remission before undergoing al-
logeneic HSCT. In April 2001 he received a myeloablative prep-
arative regimen consisting of 120 mg/kg cyclophosphamide and
1,400 cGy total body irradiation followed by infusion of G-CSF–
mobilized blood stem cells from an HLA-identical female sibling.
He remains in complete remission 2 yr after HSCT. His pro-
phylactic immunosuppressive treatment included tacrolimus and
methotrexate. 5 wk after transplantation, he developed acute
GVHD of the skin (grade 2 GVHD). Acute GVHD responded
to treatment with prednisone, daclizumab, and mycophenolate
mofetil but did not resolve completely. He was subsequently
treated for limited chronic GVHD with involvement of skin and
oral mucosa with a combination of mycophenolate mofetil, tac-
rolimus, and prednisone. Chronic GVHD persists 2 yr after trans-
plantation and the patient remains on immunosuppressive drugs.
 
Peptides.
 
Synthetic peptides were obtained from New En-
gland Peptide. Peptides were either unpurified (93 screening pep-
tides), or 
 
 
 
85% purity (DBX
 
34–47
 
, DBY
 
34–47
 
, DBX
 
30–48
 
, DBY
 
30–
48
 
, DBX
 
120–136
 
, DBY
 
118–134
 
, DBX
 
538–554
 
, DBY
 
536–552
 
). Each pep-
tide was reconstituted at 10 mg/ml DMSO and stored at 
 
 
 
20
 
 
 
C.
 
Cell Culture.
 
Patient and allogeneic EBV-transformed B cell
lines were generated by incubating PBMCs with supernatant from
EBV–producing B95-8 marmoset cells. Once established, cell
lines were maintained in RPMI 1640 supplemented with 10%
heat-inactivated FCS, 4 mM glutamine, 1 mM sodium pyruvate,
10 mM Hepes, and antibiotics. T cell lines and clones were cul-
tured in RPMI 1640 supplemented with 10% heat-inactivated
human AB serum, glutamine, sodium pyruvate, Hepes, and anti-
biotics (referred to as T cell medium) in the presence of 100 U/ml
recombinant IL-2. Medium was replenished twice weekly with
fresh IL-2. Immature DCs were obtained as previously described
(20). In brief, 40–60 
 
  
 
10
 
6 
 
PBMCs were incubated for 15 min in
a 75-cm
 
2 
 
Costar culture flask (Corning Inc.). Nonadherent cells
were removed by thoroughly washing the flask three times with
medium. The remaining adherent cells were incubated for 1 wk
in medium supplemented with 1,000 U/ml IL-4 (R&D Systems)
and 1,000 U/ml GM-CSF (R&D Systems). Cells were then har-
vested, washed, and used as immature DCs. Maturation of DCs
was achieved by incubating cells for 24 h with 25 ng/ml poly-IC
(Amersham Biosciences) or 100 ng/ml LPS (Sigma-Aldrich).
 
Generation of a DBY-reactive T Cell Clone.
 
A T cell line was
generated by stimulating 6 
 
  
 
10
 
6 
 
PBMCs collected from the pa-
tient 16 mo after HSCT in the presence of peptide DBY
 
34–50 
 
at a
final concentration of 25 
 
 
 
g/ml in the presence of 100 U/ml IL-
2. 1 wk after stimulation, CD4
 
  
 
T cells were immunopurified
from the cell line using anti-CD4
 
  
 
microbeads (Miltenyi Biotec)
and subsequently cloned by limiting dilution on feeder cells con-
sisting of irradiated patient EBV B cells (1.5 
 
  
 
10
 
4 
 
cells/well; 60
Gy) and allogeneic PBMCs (7 
 
  
 
10
 
4 
 
cells/well; 35 Gy) in the
presence of 100 U/ml recombinant human IL-2. All of the T cell
clones generated were assessed for specific reactivity with the
DBY peptide. Clone 2F9 displayed strong reactivity and was fur-
ther expanded under the same culture conditions with the addi-
tion of PHA (Invitrogen).
 
ELISPOT Assays.
 
ELISPOT assays were performed as previ-
ously described (21). In brief, 1–2 
 
  
 
10
 
5 
 
PBMCs were incubated in
duplicate cultures in the presence of 10 
 
 
 
g/ml different peptides
in multiscreen-IP microplates (Millipore) previously coated with 
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anti–IFN-
 
  
 
mAb (Mabtech). After an overnight incubation, plates
were washed six times in PBS and incubated with a biotinylated
anti–IFN-
 
  
 
mAb (Mabtech) at room temperature for 75 min. The
plates were washed again and incubated with streptavidin alkaline
phosphatase (Mabtech) for 45 min at room temperature. The plates
were finally washed and spots were revealed using nitroblue tetra-
zolium and brom-chlor-indolyl phosphate color development sub-
strates (Promega). Spots were counted in duplicate wells and results
were presented as number of spot forming cells/10
 
6 
 
PBMCs.
 
IFN-
 
  
 
Secretion Assays.
 
IFN-
 
  
 
secretion by T cell clone 2F9
was assessed by incubating 5 
 
  
 
10
 
4 
 
responder cells in 96-well,
U-bottom microplates with 5 
 
  
 
10
 
4 
 
stimulator cells in 200 
 
 
 
l T
cell medium containing 50 U/ml IL-2. Stimulator cells consisted
of autologous or allogeneic EBV B cells pulsed with synthetic
peptides (10 
 
 
 
g/ml or as otherwise stated) for 1 h at 37
 
 
 
C and
washed twice to remove excess peptide. After 18 h of incubation,
50 
 
 
 
l/well supernatant was harvested and IFN-
 
  
 
was measured
using an ELISA kit (Endogen) according to the manufacturer’s
instructions. In experiments with DCs, 10,000 immature DCs/
well were incubated in 100 
 
 
 
l medium with or without LPS or
poly-IC for 24 h at 37
 
 
 
C. 4 
 
  
 
10
 
4 
 
2F9 cells were then added to
the culture in the presence of 50 U/ml IL-2, and secretion of
IFN-
 
  
 
was measured after 18 h of incubation.
 
Cytotoxicity Assay.
 
Target cells were labeled with 
 
51
 
Cr for 1 h
at 37
 
 
 
C, washed three times, pulsed with the corresponding pep-
tide for an additional hour at 37
 
 
 
C, washed three times again, and
then plated at 2,000 cells/well in conical-bottom, 96-well micro-
plates. Clonal 2F9 cells were added at varying effector/target ra-
tios and 
 
51
 
Cr release was measured in the supernatant after 4 h of
incubation at 37
 
 
 
C. In cold target inhibition experiments, HLA-
DR
 
*
 
1501 female or male unlabeled matured DCs were incu-
bated with 
 
51
 
Cr-labeled targets at various ratios for 1 h before
adding the T cell clone.
 
Recombinant Protein Production and Western Blot Assays.
 
Re-
combinant DBX and DBY protein production and purification
has been described (19). In brief, full-length DBX and DBY
cDNA were cloned using the Gateway cloning system (Invitro-
gen) into pDEST42 prokaryotic expression vector introducing V5
and 6 HIS Tag epitopes at the protein C terminus. After transfor-
mation in 
 
Escherichia coli
 
, DBX and DBY expression was induced
with isopropyl-
 
 
 
-
 
d
 
-thiogalactopyranoside and proteins were puri-
fied from bacterial lysates by affinity chromatography on nickel
columns (Invitrogen). For Western blotting, 5 
 
 
 
g of each protein
was run by electrophoresis on a 4–12% polyacrylamide gel in de-
naturing conditions using the NuPAGE system (Invitrogen), trans-
ferred on a nitrocellulose membrane, and blocked for 1 h in block-
ing buffer (1X TBST, 5% nonfat dry milk). Membranes were
incubated overnight with either horseradish peroxidase (HRP)-
conjugated anti-V5 epitope mAb (Invitrogen) or patient serum di-
luted at 1:10 in blocking buffer, and then with HRP-conjugated
goat anti–human IgG antisera (Jackson ImmunoResearch Labora-
tories). Proteins were subsequently detected using the “Western
Lightning” chemiluminescence HRP reagents (PerkinElmer).
 
DBY ELISA Assays.
 
Antibodies to DBX and DBY recombi-
nant protein, as well as DBX and DBY peptides, were measured
by ELISA (19). In brief, high protein adherence Nunc-Immuno-
plates (Nunc) were coated overnight with either 5 
 
 
 
g/ml puri-
fied recombinant protein or 10 
 
 
 
g/ml synthetic peptides in car-
bonate-binding buffer, washed in TBST, and then blocked with
2% nonfat dry milk in TBST. Serum diluted in blocking buffer
was then added to the plates and incubated either overnight at
4
 
 
 
C for the recombinant protein–coated plates, or for 3 h at 20
 
 
 
C
for the peptide-coated plates. Plates were then washed in TBST,
incubated for 1 h at 20
 
 
 
C with alkaline phosphatase–conjugated
goat anti–human IgG antisera (Pierce Chemical Co.), diluted in
blocking buffer, washed again, and developed using pNPP alka-
line phosphatase substrate colorimetric reagents (Sigma-Aldrich).
Optical density was read at 405 nm.
 
Results
 
DBY mHA Elicits a Sustained T Cell Response after HSCT.
 
Initial experiments were designed to assess T cell reactivity
to a prototypic H-Y antigen, DBY. 93 overlapping peptides
Figure 1. DBY elicits a sustained T cell response after allogeneic
HSCT. (A) IFN-  secretion ELISPOT assay was performed using un-
stimulated PBMCs collected 15 mo after HSCT and 93 overlapping DBY
peptides distributed into 12 pools. Results are presented as number of
spot-forming cells/106 PBMCs. (B) The eight peptides included in pool-1
were tested individually using the same cells and according to the same
procedure. (C) Patient PBMCs collected at various times before and after
HSCT were tested by ELISPOT assay for reactivity to the DBY antigenic
peptide. Time 0 corresponds to a sample collected before HSCT. 
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representing the entire amino acid sequence of DBY were
synthesized and distributed in 12 pools of either 8 or 5 pep-
tides. PBMCs collected from a male patient 15 mo after re-
ceiving allogeneic stem cells from a female donor were
tested for reactivity to each peptide pool using an IFN-
 
 
 
ELISPOT assay. To avoid skewing the representation of
potential DBY-reactive cells, ELISPOT assays were per-
formed using unmanipulated PBMCs without in vitro sen-
sitization or expansion. As shown in Fig. 1 A, patient
PBMCs were highly reactive with DBY peptide pool 1 and
no T cell reactivity against any of the other 11 peptide pools
was present. Further testing of individual peptides in pool 1
demonstrated that this reactivity was specific for a single
peptide, DBY
 
34–50 
 
(Fig. 1 B). These results demonstrated the
presence of a vigorous anti-DBY T cell response in vivo 15
mo after transplant that targeted a single peptide epitope.
Although these experiments do not exclude the possibility
that T cells specific for other DBY peptides were present at
lower frequency, DBY
 
34–50 
 
was the only DBY peptide that
was recognized by unstimulated PBMCs. The high level T
cell reactivity against this peptide was confirmed by testing
unstimulated PBMCs collected at various times before and
after HSCT. As shown in Fig. 1 C, no reactivity was de-
tected by ELISPOT before transplant but persistent T cell
reactivity was present in all PBMC samples available for
testing between 8 and 21 mo after transplant.
 
The DBY Peptide-specific CD4
 
  
 
T Cell Response Is Re-
stricted By HLA-DRB1
 
*
 
1501.
 
ELISPOT experiments using
PBMCs depleted of either CD4
 
  
 
or CD8
 
  
 
T cell subsets
revealed that DBY peptide–reactive cells were only present
in the CD4
 
  
 
T cell population. PBMCs collected 16 mo
after HSCT were stimulated once with peptide DBY
 
34–50 
 
in
the presence of IL-2. After 1 wk of stimulation, CD4
 
  
 
T
cells were purified and cloned by limiting dilution. Several
CD3
 
  
 
CD4
 
  
 
T cell clones were obtained that reacted with
donor EBV-immortalized B (EBV B) cells pulsed with
DBY
 
34–50
 
. One clone, 2F9, was expanded in vitro for fur-
ther studies. TCR V
 
  
 
repertoire analysis was performed
using RNA extracted from 2F9 cells and showed the ex-
pression of a single rearranged TCR 
 
  
 
chain derived from
the RBV12.151 segment. DNA sequencing confirmed the
presence of a single TCR V
 
  
 
rearrangement.
The optimal DBY antigenic epitope was characterized by
testing the reactivity of clone 2F9 to synthetic peptides of
different lengths in dose response experiments. Starting with
the putative epitope DBY
 
34–50
 
, we tested peptide variants
with longer or shorter N and C terminus for their ability to
stimulate clone 2F9. The highest reactivity was obtained us-
ing the 19-mer peptide DBY
 
30–48
 
. As shown in Fig. 2 A,
stimulation of clone 2F9 with EBV B cells pulsed with
DBY
 
30–48 
 
was inhibited by anti–HLA class II and anti–HLA-
DR mAbs, but not by anti–HLA class I or anti–HLA-DQ
antibodies. These results indicated that TCR recognition
was restricted by HLA-DR. To determine which HLA-DR
allele was recognized by the 2F9 clone, we used a series of
allogeneic EBV B cells expressing either HLA-DRB1
 
*
 
0301
or HLA-DRB1
 
*1501, the HLA-DR alleles expressed by
both patient and donor. As shown in Fig. 2 B, cells express-
ing DRB1*1501 stimulated clone 2F9 when pulsed with the
DBY peptide, whereas cells expressing DRB1*0301 were
not recognized. These experiments indicate that the DBY30–48
peptide was specifically presented by HLA-DRB1*1501.
The T Cell Response Recognizes both DBX and DBY
Antigenic Peptides. We then tested whether clone 2F9
would also recognize the corresponding X-encoded pep-
tide, DBX30–48, which differs from DBY30–48 by two resi-
dues at positions 30 and 46. Despite the two disparate amino
acids, both X and Y peptides stimulated clone 2F9 at a sim-
ilar level (Fig. 3 A). A shorter peptide starting at residue 34,
which only included disparate position 46, was also tested.
Although less reactive than the longer peptide, the X and Y
alleles of the shorter peptide were equally recognized by
clone 2F9 (Fig. 3 A). To confirm that clone 2F9 was repre-
sentative of the T cell response that developed in vivo, we
examined the reactivity of unmanipulated patient cells to
both DBX and DBY peptides. As shown in Fig. 3 B,
equivalent reactivity against the two peptides was detected
in ELISPOT assays using unmanipulated PBMCs collected
at 8 and 21 mo after HSCT, indicating that the T cell re-
sponse in vivo also recognized both epitopes. T cell clone
2F9 also displayed substantial cytolytic activity toward pa-
tient EBV B cells pulsed with either DBY30–48 or DBX30–48
but not an irrelevant peptide, DBY536–552 (Fig. 3 C).
T Cell Clone 2F9 Recognizes Endogenously Processed DBX
and DBY Antigens in Mature DCs. Because the T cell re-
sponse did not distinguish between DBX and DBY pep-
Figure 2. The CD4  T cell response to DBY antigen is restricted by
HLA-DRB1*1501 molecules. (A) CD4  T cell clone, 2F9, was stimulated
with autologous EBV-immortalized B cells pulsed with DBY peptide
(DBY30–48) or another irrelevant DBY peptide. Anti–HLA class II mAb
(9.49) and anti–HLA-DR mAb (G46.6) blocked antigen recognition,
whereas anti–HLA class I (W6/32) or anti–HLA-DQ (SPVL.3) mAb did not.
Results represent quantitative measurement of IFN-  secretion in the cocul-
ture supernatant obtained by ELISA. (B) Clone 2F9 was stimulated with
different DBY30–48–pulsed EBV B cells (LCL) sharing the expression of either
HLA-DRB1*0301 or HLA-DB1*1501 with the patient cells. After over-
night incubation, IFN-  secretion was measured in the coculture supernatant.Zorn et al. 1137
tides, we undertook further experiments to determine
whether DBX and DBY epitopes were equally presented
after exogenous processing of full-length recombinant
protein. Using an IFN-   release assay, clone 2F9 was
tested for reactivity against HLA-DRB1*1501 male DCs
pulsed with recombinant DBX and DBY proteins as well
as a control irrelevant recombinant protein (HIV p24).
Clone 2F9 responded to DCs pulsed with either of the
three recombinant proteins but not to unpulsed DCs (un-
published data). These results suggested that maturation of
DCs might result in presentation of endogenous DBY or
DBX epitopes to the T cells. We then tested the capacity
of female and male DCs matured with synthetic poly-IC
or LPS to stimulate T cell clone 2F9. As shown in Fig. 4
A, both male and female DCs were recognized after in
vitro maturation, indicating that both endogenous DBX
and DBY epitopes were processed and presented to the T
cell clone. In both male and female DCs, T cell recogni-
tion was inhibited by anti–HLA-DR mAb (Fig. 4 A). The
endogenous processing of DBX and DBY peptides in ma-
ture female and male DCs was further confirmed in cold
target inhibition experiments. As shown in Fig. 4 B, cy-
tolytic activity of clone 2F9 toward DBY30–48–pulsed and
51Cr-labeled EBV B cells was significantly inhibited by the
addition of unlabeled female or male DCs that had previ-
ously been matured with LPS.
DBY Induces an Antibody Response after Allogeneic HSCT.
To further characterize the immune response to DBY and
DBX, we also determined whether an antibody response to
these antigens developed after allogeneic transplantation.
Using an ELISA assay, serum samples collected at various
Figure 3. DBX and DBY epitopes are both recognized by patient T cells. (A) 2F9 T cells were stimulated with autologous EBV B cells pulsed with
different concentrations of DBX and DBY peptides. IFN-  secretion was measured in the coculture supernatant after overnight incubation. The optimal
19-mer DBX and DBY peptides are shown in   and  , respectively. Shorter, 14-mer suboptimal epitopes are also shown (  and  ). Disparate residues
between DBX and DBY versions of the peptides are represented with bold underlined characters. Peptide concentrations are expressed in microgram/
milliliter. (B) IFN-  secretion ELISPOT assays were performed using unstimulated PBMCs collected 8 and 21 mo after HSCT and both DBX30–48 and
DBY30–48 peptides. (C) Clone 2F9 cytolytic activity was tested against EBV B cells pulsed with either DBX30–48 ( ), DBY30–48 ( ), or an irrelevant
peptide, DBY536–552 ( ).
Figure 4. T cell clone 2F9 recognizes DBX and DBY antigens endog-
enously processed and presented by mature DCs. (A) Female and male
HLA-DRB1*1501 DCs (104/well) were incubated for 24 h with medium
alone or poly-(I)-poly-(C) to induce maturation. T cell clone 2F9 (104/
well) was then added to the wells in the presence of IL-2. After 18 h of
incubation, secretion of IFN-   was determined in cocultures using
ELISA. (B) Clone 2F9 cytolytic activity toward DBY30–48–pulsed 51Cr-
labeled EBV B cells (LCL) at an E/T ratio of 1:1 was inhibited by the addi-
tion of mature unlabeled HLA-DRB1*1501 female or male DCs. Three
ratios of unlabeled/labeled targets were tested in this experiment.B and T Cell Response to mHA after Allogeneic HSCT 1138
times before and after HSCT were tested for the presence
of IgG antibody to recombinant DBY protein. Titration
curves shown in Fig. 5 show the presence of antibody reac-
tive with DBY protein starting 12 mo after transplantation
and increasing thereafter. No reactivity was detected before
or 6 mo after transplant, indicating that the antibody re-
sponse developed relatively late after HSCT. Remarkably,
the DBY-specific CD4  T cell response was readily detect-
able 8 mo after transplantation (Fig. 1 B). Taken together,
these data provide evidence for the development of a coor-
dinated T and B cell immune response to DBY antigen af-
ter allogeneic HSCT.
The Antibody Response Is Specific for DBY Antigen. The
specificity of the antibody response measured by ELISA
was also examined by Western blot. As shown in Fig. 6,
immunoblotting with an anti-V5 epitope antibody demon-
strated equivalent loading of recombinant DBY and DBX.
Patient serum collected 21 mo after HSCT was only reac-
tive with DBY and not with recombinant DBX protein. In
contrast to the T cell response, which did not appear to dif-
ferentiate between DBX and DBY epitopes, the antibody
response was specific for DBY.
The DBY-specific Antibody Response Continues to Evolve 21
mo after HSCT. To further characterize the antibody re-
sponse after allogeneic HSCT, the same set of 93 overlap-
ping peptides used in the ELISPOT experiments was used
in ELISA to define the specificity of the antibody response.
As shown in Fig. 7 A, serum collected 16 mo after HSCT
was reactive with a single DBY peptide (DBY118–134), dis-
Figure 5. DBY antigen elicits an antibody response after HSCT. IgG
antibodies to recombinant DBY protein were detected by ELISA in patient
serum samples collected at various times after allogeneic HSCT. Results
are presented as serum titrations. Nonspecific reactivity to a control recombi-
nant protein (HIV p24) was subtracted from each value.
Figure 6. The antibody response after HSCT is specific for DBY antigen.
DBX and DBY recombinant proteins were separated by SDS-PAGE
electrophoresis, transferred on nitrocellulose membrane, and immuno-
blotted with either an anti-V5 mAb (left) or patient serum collected 21
mo after HSCT (right). Degradation products generating distinct patterns
for DBX and DBY are noticeable in the figure.
Figure 7. The antibody response to DBY continues to evolve 21 mo
after HSCT. (A) Patient serum collected 16 mo after transplant was used
to map the DBY-specific antibody response. The serum was diluted at 1:10
and tested by ELISA for reactivity with each of the 93 overlapping DBY
peptides. (B) The same experiment was repeated using identical procedures
with serum collected 21 mo after HSCT.Zorn et al. 1139
tinct from the T cell epitope. The same reactivity was
found with patient serum collected 5 mo later. However,
the 21-mo sample also reacted with an additional epitope,
DBY536–552 (Fig. 7 B). These results indicate that the anti-
body response to DBY antigen continued to evolve almost
2 yr after transplant by targeting a new DBY epitope. Both
of the DBY peptides recognized by patient serum con-
tained amino acid polymorphisms that are not present in
DBX. The specificity of the antibody response for DBY
antigen was therefore tested in ELISA using corresponding
DBX and DBY peptides. Results of this analysis shown in
Fig. 8, confirm that the antibody response was specifically
directed against the two DBY peptides but not to the cor-
responding DBX peptides. In this experiment, peptides
representing both DBX and DBY T cell epitopes were also
tested and no antibody response to either of these peptides
was detected in patient serum.
Discussion
mHAs play a critical role in GVHD and GVL immune
responses after allogeneic HSCT. Several mHAs have previ-
ously been characterized in humans including four autoso-
mal and eight H-Y T cell epitopes (5–8, 10–17). With only
two exceptions (14, 17), these antigens have been found to
be HLA class I–restricted peptides recognized by CD8 
CTLs. Increased numbers of CD8  CTLs specific for some
of these mHAs have been found in patients with active
acute GVHD (22), but the role of mHA-specific CD4  T
cells in the pathogenesis of GVHD has received less atten-
tion. To date, only one HLA class II–restricted human
mHA has been identified in T cells from a patient with
acute GVHD (14) and another HLA class II–restricted
mHA has been identified as a target of hematopoietic graft
rejection (17). Here we describe a new HLA class II–
restricted mHA presented by HLA-DRB1*1501 and recog-
nized by CD4  helper T cells. This epitope is the first T cell
mHA associated with chronic GVHD. Like one of the pre-
viously identified HLA class II mHAs, this antigen is en-
coded by the male-specific gene DBY. Interestingly, an-
other class II–restricted antigen encoded by DBY has also
been identified in a murine model of GVHD after female to
male transplantation (23). These observations in different
species as well as the association with both acute and
chronic GVHD suggest that DBY antigens are highly im-
munogenic to CD4  female T cells that have not previously
been exposed to these antigens during thymic maturation.
By using unstimulated PBMCs in our ELISPOT assay,
we unequivocally demonstrated a relatively high level of
expansion of DBY-specific T cells in vivo after transplanta-
tion. Phenotypic analysis of patient PBMCs 21 mo after
HSCT showed that  25% of PBMCs were CD3  CD4  T
cells (not depicted). Because the peptide ELISPOT assay
detected   75 spot-forming cells/106  PBMCs, the fre-
quency of CD4  T cells specific for a single DBY peptide
can be calculated to be  0.03%. This relatively high fre-
quency is similar to that observed for EBV-specific CD4 
T helper cells (24). This high level of expansion of DBY-
specific CD4  T cells persisted for more than 1 yr and co-
incided with persistence of active chronic GVHD that
required continuous immune-suppressive therapy. The per-
sistence of this vigorous T cell response despite immune-
suppressive therapy also suggests a high level of ongoing
antigenic stimulation in vivo and an important role for
DBY-specific T cells in the pathogenesis of chronic GVHD
in this individual.
Among the 93 peptides representing the complete amino
acid sequence of DBY, only 1 peptide was recognized by
unstimulated patient cells. Although we cannot exclude the
possibility that other DBY epitopes were also targeted, the
DBY30–48 epitope appeared to be highly immunodominant
in the immune response to DBY. Vogt et al. (14) have
previously identified a different antigenic DBY peptide,
DBY176–187, presented by HLA-DQ5. In their study, the
corresponding DBX homologue was not recognized by the
DBY-specific T cell clone, and X-Y–disparate residues in-
cluded in the epitope were shown to be critical for its rec-
ognition by donor T cells. DBY30–48 also contains two
amino acids that distinguish this peptide from its DBX ho-
mologue, but unlike the epitope presented by HLA-DQ5,
both DBY30–48 and DBX30–48 were presented by HLA-
DRB1*1501 and recognized by the CD4  T cell clone. In
dose-response experiments, the T cell clone responded
equally well to autologous EBV B cells pulsed with either
peptide. Similarly, patient PBMCs obtained at different
times after transplant also responded similarly to both pep-
tides. Class II–restricted epitopes are usually composed of a
9-mer core peptide flanked by stretches of amino acids on
each side (25). The core peptide interacts directly with the
HLA groove and the TCR, whereas flanking regions,
sticking out of the HLA groove provide additional stability
to the complex. In DBY30–48, the putative 9-mer core is
100% identical between DBX and DBY homologues. The
only disparate residues are located in the flanking regions
and these amino acids do not appear to affect the affinity
for HLA class II molecules (DRB1*1501) or recognition by
the TCR. In our experiments, relatively high concentra-
tions of antigenic peptides were required to trigger re-
sponse of the 2F9 clone, suggesting that these cells express a
low affinity TCR. Remarkably, T cells specific for the pre-
Figure 8. Antibody responses after HSCT are specific for DBY antigen.
Patient serum collected 21 mo after HSCT was tested in ELISA for reac-
tivity with two DBY B cell epitopes, the corresponding DBX peptides,
and both DBY and DBX T cell epitopes. Peptide sequences are shown
with the X-Y–disparate residues noted with bold underlined characters.B and T Cell Response to mHA after Allogeneic HSCT 1140
viously characterized DQ5-restricted DBY peptide were
also dependent on similarly high concentrations of peptide
antigens in functional assays (14). It is currently unknown
whether a general trend can be established from these two
individual cases.
Polymorphic residues need not be included in the actual
T cell epitope to influence the immunogenicity of an anti-
gen. For example, recognition of HA-8 mHA results from
the differential processing of an allelic gene product due to
polymorphic residues located outside the actual epitope
(6). We considered this possibility for DBY30–48 but we did
not find any evidence of differential processing of the
DBX and DBY homologous peptides. Importantly, both
male and female DCs expressing HLA-DRB1*1501 were
recognized at the same level after maturation. In addition,
male and female DCs were equally effective in cold target
inhibition assays, confirming the endogenous expression
and recognition of both the DBY30–48 and DBX30–48 pep-
tides by mature DCs. In these experiments, the processing
of DBY30–48 followed the endogenous pathway of presen-
tation similar to what has previously been described for
DBY176–187 (14). However, the presentation of DBY30–48
required maturation of the DCs with either poly-IC or
LPS. Previous studies have demonstrated that antigen pro-
cessing in DCs is modified during maturation, resulting in
the presentation of a new range of cryptic peptide antigens
at the cell surface (26). Our findings suggest a similar
method of antigen presentation for both DBY30–48 and
DBX30–48 epitopes.
In addition to DBY-reactive T cells, the patient also de-
veloped an antibody response to the same antigen. Using
synthetic DBY peptides we mapped the antibody response
to two distinct B cell epitopes. In previous experiments we
found that antibody responses specific for DBY mHA de-
veloped in  50% of male patients who received stem cell
transplants from female donors (19). A map of the common
DBY B cell epitopes was also established, demonstrating
that antibody responses were primarily directed against re-
gions of disparity between DBY and DBX. The two
epitopes identified in this study are among these frequently
targeted epitopes. It is interesting to note, however, that
both DBY T cell epitopes characterized thus far (DBY30–48
and DBY176–187) were not found to be common B cell tar-
gets, presumably because the corresponding portions of the
DBY protein are not readily accessible to the B cell re-
ceptor. These results further illustrate the complementary
function of the two arms of the adaptive immune system to
cover a wide range of epitopes within a given antigen.
Antibodies to a single DBY epitope first developed be-
tween 6 and 12 mo after HSCT, the date of the first reac-
tive sample. Subsequently, the titer of this antibody re-
sponse gradually increased until 16 mo after transplant. The
acquisition of a new B cell antigen between 16 and 21 mo
provided further evidence that B cell immunity to DBY
was still evolving at that time. In comparison, the CD4 
helper T cell response, which was first detected 8 mo af-
ter  transplant, continued to be directed against a single
epitope. Also in contrast to the T cell response, the B cell
response was specific for DBY and did not cross-react with
recombinant DBX in Western blot assays. Antibody speci-
ficity for DBY was confirmed at the peptide level using an
ELISA assay. Thus, although the patient developed both T
and B cell immunity to DBY after HSCT, these results
show that it was only the B cell response that distinguished
between DBY and DBX.
After allogeneic HSCT, the patient developed acute
GVHD, which evolved into chronic GVHD 3–4 mo after
transplant. Therefore, our experiments were performed pri-
marily with samples collected in the context of chronic
GVHD. In this respect, the dual recognition of DBX and
DBY by patient T cells is remarkable as it suggests the de-
velopment of T cell immunity to an autoantigen. Similari-
ties between chronic GVHD and autoimmune diseases
have been well documented. In particular, common skin
lesions in chronic GVHD are often similar to those seen in
scleroderma or systemic lupus erythematosus. A striking
hallmark of autoimmune diseases is the development of an-
tibodies as well as T cells reactive with a variety of autoanti-
gens (27). Based on our findings, it is attractive to speculate
that coordinated B and T cell responses similarly contribute
to the pathogenesis of chronic GVHD. Donor specificity
for recipient mHA is likely to be required for initiation of
acute GVHD, but our studies suggest that the subsequent
development of chronic GVHD might be associated with
the recognition of T cell epitopes that do not discriminate
between recipient and donor cells. Nevertheless, mainte-
nance of chronic GVHD might be dependent on continu-
ing specific recognition of recipient antigens by donor B
cells. Although DBY is not expressed on the cell surface,
this protein is widely expressed in many tissues and anti-
DBY antibodies may contribute to the formation of im-
mune complexes, which can enhance the uptake and pre-
sentation of the antigen from dying cells. As noted in our
studies, maturation of DCs by nonspecific mechanisms can
also lead to the presentation of DBY epitopes to donor T
cells in vivo. Taken together, these mechanisms may well
be contributing to the persistence of chronic GVHD in the
patient we studied. Further studies in other individuals will
be needed to confirm whether similarly coordinated B and
T cell immune responses are commonly found in patients
with chronic GVHD. In this regard, it should also be noted
that DBY is only one of several Y-encoded proteins with
closely related X homologues that are widely expressed in
many tissues. Similar responses to other H-Y antigens may
also play a role in the pathogenesis of chronic GVHD.
Previous mHA have been identified using T cells estab-
lished in vitro and selected for their ability to differentially
recognize recipient cells from donor cells in functional as-
says. Although such approaches have resulted in the charac-
terization of several target antigens of acute GVHD, this
method also biases the type of target epitopes that can be
identified. In our series of experiments, unselected patient
T cells were screened for reactivity against a large panel of
potential target peptides. We subsequently isolated the re-Zorn et al. 1141
active cells in vitro and further analyzed the specificity of
the immune response. The dual recognition of DBX and
DBY peptides was unexpected and illustrates the validity of
our screening strategy for the identification of relevant an-
tigens in GVHD. Although T cells specific for this new
DBY epitope persisted at high levels for more than 1 yr,
these cells would not have been detected if only clones re-
active with recipient cells and not donor cells had been se-
lected to characterize the GVHD response.
In summary, this study represents the first demonstration
of a coordinated T cell–B cell response to mHA in the
clinical context of chronic GVHD. These studies reveal a
complex immune response that includes elements of au-
toimmunity as well as alloimmunity. The alloimmune re-
sponse to DBY appears to be mediated primarily by donor
B cells. In contrast, the autoimmune response to both DBY
and DBX is mediated primarily by donor CD4  T cells.
These observations further emphasize the intricate balance
that develops during reconstitution of donor immunity af-
ter allogeneic stem cell transplantation when immunologic
distinctions between autoantigens and persisting alloanti-
gens become uncertain.
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